Distinguishing between HER2-negative (0) and HER2-low (1+) tumours has become increasingly important, as HER2-low cases comprise more than 50% of breast cancers and HER2-low status serves as a clinically validated, predictive biomarker of benefit from trastuzumab deruxtecan treatment [58,81]. This evidence concerns the gene ERBB2 and neoplasm.